Examples of using Efficacy endpoint in English and their translations into Swedish
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Ecclesiastic
-
Official/political
-
Computer
-
Programming
-
Political
Efficacy endpoint or haematological parametera.
Table 3: Primary and secondary efficacy endpoints in LAL-CL02.
As secondary efficacy endpoint overall survival(Table 6) was assessed.
Table 4- Analysis of primary and secondary efficacy endpoints PLATO.
Secondary efficacy endpoints included OS and ORR.
People also translate
The number of oocytes retrieved was a key secondary efficacy endpoint.
Effect of ivacaftor on other efficacy endpoints in studies 1 and 2.
The treatment effect of icatibant was confirmed by secondary efficacy endpoints.
Effect of ivacaftor on other efficacy endpoints in studies 1 and 2 Study 1.
Twelve-month persistent infection was evaluated as additional efficacy endpoint.
Table 3: Summary of Efficacy Endpoints at Day 35 Intent to Treat Population.
Summary of efficacy analyses in the VISTA study Efficacy endpoint Time to progression.
Secondary efficacy endpoints were pCR rate in the breast(ypT0/is),
Additionally, fewer MACE events were observed with FARXIGA for the other primary efficacy endpoint, however, this did not reach statistical significance.
Secondary efficacy endpoints were objective response rate(ORR)
Table 1: Co-primary and Selected Secondary Efficacy Endpoints at End of Treatment for Pooled Studies.
Secondary efficacy endpoints included progression-free survival
successfully met its primary efficacy endpoint.
Secondary efficacy endpoints included Progression Free Survival
at Week 48(secondary efficacy endpoint) in the intent to treat(RD=F) analysis.
The study met its primary efficacy endpoint for both pasireotide intramuscular use doses.
PX 171-003A1 was a single-arm phase 2 study(N 266; exposure to≥ 2 prior therapies required), which met its primary efficacy endpoint of IRC-assessed ORR 22.9.
Secondary efficacy endpoints included Progression Free Survival
The mean absolute change from baseline through week 8 in percent predicted FEV1(primary efficacy endpoint) was 7.5% in the ivacaftor period
Primary efficacy endpoint(International Myeloma Working Group criteria)
Serum anti- HBs trough levels of 100 IU/l and higher(primary efficacy endpoint) were maintained for all patients during the 18 to 24 week trial period.
The key efficacy endpoint was the sponsor-defined clinical outcome at test-of-cure(TOC),
The mean absolute change from baseline through week 16 in percent predicted FEV1(primary efficacy endpoint) was 1.5 percentage points in the ivacaftor group and -0.2 percentage points in the placebo group.
Secondary efficacy endpoints included post-transplant response rates(CR+nCR,
The mean absolute change from baseline through week 24 in percent predicted FEV1(primary efficacy endpoint) was 2.57 percentage points in the ivacaftor group and 0.46 percentage points in the placebo group.